Adamas Pharmaceuticals (ADMS) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Adamas Reports First Quarter 2015 Financial Results
May 13, 2015 4:00 PM EDTEMERYVILLE, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the first quarter of 2015.
"In 2015, we have made continued progress throughout our business, including receiving orphan drug designation for our lead product candidate, ADS-5102, for the treatment of levodopa-induced dyskinesia (LID), a complication associated with the treatment of Parkinson's disease and further increasing our patent estate," said Gregory T. Went, Ph.D., Chairman and CEO of Adamas Pharmaceuticals, Inc. "In the coming months, we look forward to expanding our wholly-owned product pipeline with the... More
